Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 22, 2026Journal of Rare DiseasesOpen Access

Analytical dissection of CRISPR-Cas9-mediated gene editing fidelity: integrating next-generation bioanalytical platforms for precision immunotherapeutics and rare disease correction

View Full Paper
Ask AI
Bookmark
Share

Authors

AMA. M. Mukherjee

Discussion

Loading...

Member takes

Overview

Review discusses CRISPR gene editing accuracy in immunotherapy and rare diseases, indicating a need for improved assessments.

Key Points

  • The aim is to evaluate gene editing fidelity in CRISPR-Cas9 therapeutics beyond traditional measures.
  • Analytical and translational frameworks for assessing CRISPR fidelity were reviewed.
  • Recent bioanalytical technologies including digital droplet PCR and various off-target mapping techniques were highlighted.
  • Discussion on integrative scoring and AI-assisted models for analyzing editing outcomes.
  • Multi-layered analyses reveal context-dependent variability in gene editing outcomes.
  • New approaches detected previously undetected off-target effects, implicating therapeutic safety.
  • Challenges in assay standardization and validation were identified, emphasizing the need for harmonization.

Cite This Study

A. M. Mukherjee (2026) studied this question.

synapsesocial.com/papers/6a605d764163e025518d78cchttps://doi.org/10.1007/s44162-026-00220-3
View Full Paper
Ask AI
Bookmark
Share